Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
Emmaus Life Sciences, Inc. amended convertible notes of $9 million with note holders at 10% per annum, payable semi-annually maturing February 24, 2025.
- Instrument
- convertible notes
- Principal
- $9 million
- Counterparty
- note holders
- Rate
- 10% per annum, payable semi-annually
- Maturity
- February 24, 2025
- Event
- amendment
Exact text from the filing
On February 21, 2024, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement pursuant to which we agree to issue $9 million principal amount of convertible promissory notes of the company due February 24, 2025 (the “Exchange Notes”) in exchange for the surrender for cancellation and satisfaction in full of a like principal amount of our outstanding convertible promissory notes due February 24, 2024.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Emmaus Life Sciences, Inc. entered into Exchange Agreement with note holders valued at $9 million principal amount of convertible promissory notes (effective 2024-02-21).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- note holders
- Value
- $9 million principal amount of convertible promissory notes
- Effective
- 2024-02-21
Exact text from the filing
On February 21, 2024, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement pursuant to which we agree to issue $9 million principal amount of convertible promissory notes of the company due February 24, 2025 (the “Exchange Notes”) in exchange for the surrender for cancellation and satisfaction in full of a like principal amount of our outstanding convertible promissory notes due February 24, 2024.
View on SEC.gov